Results 121 to 130 of about 1,647,688 (179)

Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo.

JAMA Dermatol
Metz M, Zeidler C, Hawro T, Pereira M, Maurer M, Bonnekoh H, Krause K, Pritchard T, Kwatra SG, Ständer S, Weller K.   +10 more
europepmc   +1 more source

Treatment of immunotherapy-associated pruritus and prurigo nodularis refractory to dupilumab with nemolizumab. [PDF]

JAAD Case Rep
Luo AJ, Rajabi F, Kashaf S, Leventhal JS.   +3 more
europepmc   +1 more source

Novel intralesional nemolizumab for chronic scalp prurigo nodularis. [PDF]

JAAD Case Rep
Gaven E, Siddiqui S, Stout M.
europepmc   +1 more source

Beyond Histamine: Mast Cell-Neuron Communication in Chronic Pruritic and Pain Disorders. [PDF]

Exp Dermatol
Kagan T, Yosipovitch G.
europepmc   +1 more source

Clinical Outcomes of Abrocitinib in Prurigo Spectrum Disorders: A Case Series. [PDF]

Cureus
Chakravadhanula U, Nagarajan M, Bhat S.
europepmc   +1 more source

Use of dupilumab in the management of refractory prurigo nodularis in an immunosuppressed double transplanted patient. [PDF]

An Bras Dermatol
Valenzuela Godoy D, Agüero R, Kolbach M.   +2 more
europepmc   +1 more source

Targeting type 2 inflammation in dermatology: mechanisms and clinical implications. [PDF]

Front Immunol
Khalil N, Farhadi L, Yosipovitch G.
europepmc   +1 more source

Literature Review: Recent Therapeutic Advances in The Management of Prurigo Nodularis: From Conventional Therapy to Biologics and Targeted Small-Molecule Agents. [PDF]

Clin Cosmet Investig Dermatol
Avriyanti E, Larasati R, Rengasamy S, Hidayah RMN, Tsaqilah L, Pangastuti M, Maharani RH.   +6 more
europepmc   +1 more source

Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report. [PDF]

Front Immunol
Liao X, Lu Y.
europepmc   +1 more source